NRXS
AMEXNeuraxis Inc.
News25/Ratings0
News · 26 weeks44+17%
2026-04-192026-10-11
Mix3090d
- Insider15(50%)
- SEC Filings6(20%)
- Other4(13%)
- Earnings2(7%)
- Leadership2(7%)
- Market1(3%)
Latest news
25 items- PRNeurAxis Announces Medical Policy Coverage Milestone, Expanding Access to 26 Million Additional Covered LivesCARMEL, Ind., Oct. 15, 2026 (GLOBE NEWSWIRE) -- NeurAxis, Inc. ("NeurAxis" or the "Company") (NYSE:NRXS), a medical technology company commercializing neuromodulation therapies for chronic and debilitating conditions in children and adults, today announced significant new medical policy coverage from a major national health insurer for Percutaneous Electrical Nerve Field Stimulation ("PENFS"). The coverage spans multiple states and represents approximately 26 million medical plan members. NeurAxis’ proprietary PENFS technology, IB-Stim, is FDA-cleared for the treatment of functional abdominal pain associated with irritable bowel syndrome (IBS) and Functional Dyspepsia (FD) including assoc
- SECSEC Form 8-K filed by Neuraxis Inc.8-K - Neuraxis, INC (0001933567) (Filer)
- INSIDERSEC Form 4 filed by Neuraxis Inc.4 - Neuraxis, INC (0001933567) (Issuer)
- INSIDERSEC Form 4 filed by Neuraxis Inc.4 - Neuraxis, INC (0001933567) (Issuer)
- INSIDERSEC Form 4 filed by Neuraxis Inc.4 - Neuraxis, INC (0001933567) (Issuer)
- INSIDERSEC Form 3 filed by new insider Blanchard Craig Thomas3 - Neuraxis, INC (0001933567) (Issuer)
- PRNeurAxis Positions for Next Phase of Commercial Growth with Appointment of Craig Blanchard as Chief Commercial OfficerCARMEL, Ind., Sept. 29, 2026 (GLOBE NEWSWIRE) -- NeurAxis, Inc. ("NeurAxis" or the "Company") (NYSE:NRXS), a medical technology company commercializing neuromodulation therapies for chronic and debilitating conditions in children and adults, today announced the appointment of Craig Blanchard as Chief Commercial Officer. In this role, Mr. Blanchard will oversee the Company’s commercial functions, including sales and marketing. The appointment of Mr. Blanchard as Chief Commercial Officer represents a strategic investment in the significant growth opportunity NeurAxis sees ahead. With the Company expecting to expand its commercial organization alongside a substantial increase in covered live
- PRNeurAxis Announces Medical Coverage Policy Milestone, Expanding Access to Over 18 million additional Covered LivesCARMEL, Ind., Sept. 16, 2026 (GLOBE NEWSWIRE) -- NeurAxis, Inc. ("NeurAxis" or the "Company") (NYSE:NRXS), a medical technology company commercializing neuromodulation therapies for chronic and debilitating conditions in children and adults, today announced significant new medical policy coverage from a major national health insurer for Percutaneous Electrical Nerve Field Stimulation ("PENFS"). The coverage spans multiple states and represents approximately 18 million health plan members. NeurAxis’ proprietary PENFS technology, IB-Stim, is FDA-cleared for the treatment of functional abdominal pain associated with irritable bowel syndrome (IBS) and Functional Dyspepsia (FD) including assoc
- PRNeurAxis to Participate in the Lytham Partners Fall 2026 Investor ConferenceCARMEL, Ind., Sept. 16, 2026 (GLOBE NEWSWIRE) -- NeurAxis, Inc. ("NeurAxis," or the "Company") (NYSE:NRXS), a medical technology company commercializing neuromodulation therapies for chronic and debilitating conditions in children and adults, will participate in a webcast presentation and host one-on-one meetings with investors at the Lytham Partners Fall 2026 Investor Conference, taking place virtually on September 29-30, 2026. Company Webcast The webcast presentation will take place at 11:45 a.m. ET on Tuesday, September 29, 2026. The webcast can be accessed by visiting the conference website at https://lythampartners.com/fall2026/ or directly at https://app.webinar.net/lJ5aBmzWwkZ. Th
- NEWSiAccess Alpha Virtual Best Ideas Fall Investment Conference, September 15-16, 2026RALEIGH, NC / ACCESS Newswire / September 8, 2026 / iAccess Alpha today announced that it will host its Virtual Best Ideas Fall Investment Conference on September 15-16, 2026, bringing together small and microcap public companies and investors for two days of company presentations and 1x1 meetings. The conference will begin on Tuesday, September 15, 2026, with a series of live-streamed company presentations. The second day, Wednesday, September 16, 2026, will be dedicated to 1x1 meetings between presenting companies and pre-qualified investors.How to AttendInvestors and industry professionals may register to view presentations and request 1x1 meetings by visiting the official event website:
- INSIDERCMO, SVP Science & Tech Miranda Adrian was granted 199,106 shares (SEC Form 4) to satisfy tax liability4 - Neuraxis, INC (0001933567) (Issuer)
- INSIDERCRO, CCO, CPO Carrico Thomas Joeseph was granted 193,678 shares, increasing direct ownership by 3,418% to 199,345 units (SEC Form 4) (tax liability)4 - Neuraxis, INC (0001933567) (Issuer)
- INSIDERChief Executive Officer Carrico Brian Allen was granted 199,188 shares, increasing direct ownership by 708% to 227,336 units (SEC Form 4) to satisfy withholding obligation4 - Neuraxis, INC (0001933567) (Issuer)
- SECNeuraxis Inc. filed SEC Form 8-K: Leadership Update, Other Events8-K - Neuraxis, INC (0001933567) (Filer)
- INSIDERDirector Watkins Bradley Mitchell was granted 26,073 shares, increasing direct ownership by 56% to 72,408 units (SEC Form 4)4 - Neuraxis, INC (0001933567) (Issuer)
- INSIDERSEC Form 4 filed by CMO, SVP Science & Tech Miranda Adrian4 - Neuraxis, INC (0001933567) (Issuer)
- INSIDERDirector Keyser Jane Elizabeth was granted 26,073 shares, increasing direct ownership by 56% to 72,408 units (SEC Form 4)4 - Neuraxis, INC (0001933567) (Issuer)
- INSIDERSEC Form 4 filed by Chief Financial Officer Henrichs Timothy Robert4 - Neuraxis, INC (0001933567) (Issuer)
- INSIDERDirector Ferge Kristin A was granted 31,134 shares, increasing direct ownership by 87% to 67,072 units (SEC Form 4)4 - Neuraxis, INC (0001933567) (Issuer)
- INSIDERSEC Form 4 filed by CRO, CCO, CPO Carrico Thomas Joeseph4 - Neuraxis, INC (0001933567) (Issuer)
- INSIDERSEC Form 4 filed by Chief Executive Officer Carrico Brian Allen4 - Neuraxis, INC (0001933567) (Issuer)
- INSIDERDirector Aharon Gil was granted 86,224 shares, increasing direct ownership by 136% to 80,058 units (SEC Form 4)4 - Neuraxis, INC (0001933567) (Issuer)
- PRNeurAxis Reports Record Second Quarter 2026 Financial Results Driven by 116% Year Over Year Revenue GrowthCARMEL, Ind., Aug. 11, 2026 (GLOBE NEWSWIRE) -- NeurAxis, Inc. ("NeurAxis," or the "Company") (NYSE:NRXS), a medical technology company commercializing neuromodulation therapies for chronic and debilitating conditions in children and adults, today announced results for the second quarter period ended June 30, 2026. 2Q26 Financial Highlights Revenues increased 116% year over year to $1.9M, reflecting continued growth from the Category I CPT code assignment for Percutaneous Electric Nerve Field Stimulation (PENFS) effective January 1, 2026, substantially increasing payer coverage.Expanded gross margin by 230 basis points as significantly more devices were sold at full reimbursement price r
- SECSEC Form 10-Q filed by Neuraxis Inc.10-Q - Neuraxis, INC (0001933567) (Filer)
- PRNeurAxis Expands Payer Coverage with New PoliciesCARMEL, Ind., Aug. 04, 2026 (GLOBE NEWSWIRE) -- NeurAxis, Inc. ("NeurAxis" or the "Company") (NYSE:NRXS), a medical technology company commercializing neuromodulation therapies for chronic and debilitating conditions in children and adults, today announced additional medical policy coverage for Percutaneous Electrical Nerve Field Stimulation (PENFS), representing over 500,000 covered lives. This coverage will expand incremental access to IB-Stim treatment for beneficiaries in the Mid-Atlantic region. "As we continue to make meaningful progress with the nation's largest payers, adding coverage from regional health plans like these broadens patient access and strengthens our reimbursement n
NRXS FAQ
5 questionsWhere does NRXS stock trade?
Neuraxis Inc. (NRXS) is listed on AMEX.What sector and industry is NRXS in?
Neuraxis Inc. operates in the Health Care sector, Biotechnology: Electromedical & Electrotherapeutic Apparatus industry.When did Neuraxis Inc. go public?
Neuraxis Inc. (NRXS) completed its IPO in 2023.What companies are similar to NRXS?
Notable peers in the same industry include MDT (Medtronic plc.), MASI (Masimo Corporation), SEAS (SeaWorld Entertainment Inc.), LIVN (LivaNova PLC), ITGR (Integer Holdings Corporation). Compare NRXS side-by-side with any of them on Quantisnow.How can I track NRXS on Quantisnow?
Quantisnow aggregates Neuraxis Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow NRXS to receive live email and push alerts on every new disclosure.